PHILADELPHIA --(July 11, 2017)-- Researchers at The Wistar Institute, an international leader in biomedical research in the fields of cancer, immunology and infectious diseases, with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of
a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).
Not exact matches
The
study, funded by the NIH / NIAAA, also
demonstrates the great potential value of
preclinical studies for understanding human disorders.
«This
study for the first time shows increased expression of IL - 33 in AMD and further
demonstrates a role for glia - derived IL - 33 in the accumulation of myeloid cells in the outer retina, loss of photoreceptors, and functional impairment of the retina in
preclinical models of retina stress,» the authors note.
This proof - of - concept
study used
preclinical models to
demonstrate that the device was effective in reducing the cancerous tumour in the living brain.
The UNC Lineberger researchers
demonstrated in
preclinical studies they could successfully design nanoparticles to capture mutated proteins released by tumors.
Preclinical studies have
demonstrated the effect of acupuncture.